Tag: haemodialysis access
Xeltis receives IDE approval from US FDA for haemodialysis vascular access...
Xeltis has announced that it has gained approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) submission to...
Xeltis starts pivotal clinical trial of “first-ever” restorative synthetic haemodialysis access...
Xeltis announced today the initiation of a pivotal trial with the “first-ever” restorative synthetic haemodialysis access grafts, dubbed ‘Axess’.
The first two patients have been...
Xeltis presents “promising” first-in-human data on restorative haemodialysis access graft
Xeltis today announced what it describes as “very promising” preliminary efficacy and safety results from one of the centres participating in the AXESS study—a...
Amplifi vein dilation system demonstrates “encouraging” clinical results in haemodialysis access
Artio Medical has announced that full results from its first-in-human clinical study of the Amplifi vein dilation system were presented at the 2021 VEITHSymposium...
Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data
The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
Results from first-in-human study of Amplifi vein dilation system presented at...
Preliminary clinical results from a first-in-human study assessing the Amplifi vein dilation system (Artio Medical) were presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October...
Artio Medical completes enrolment of first-in-human trial investigating Amplifi vein dilation...
Artio Medical announced today it has completed enrolment in its first-in-human study evaluating the Amplifi vein dilation system. In the study, five patients were treated...
More mixed results for DCBs in AV access maintenance as evidence...
Additional randomised controlled data regarding the effectiveness of drug-coated balloons (DCBs) in maintaining arteriovenous (AV) access offers new evidence, but it is freighted with...
A thumbnail sketch of haemodialysis access: Past, present, and future in...
Bart Dolmatch gives an overview of the history of haemodialysis access in the USA, and balances the pros and cons of current access options....
Addressing the data deficit for drug-coated balloon use in dialysis access
The first 24-month data from the LUTONIX AV investigational device exemption trial were presented at the Charing Cross Symposium in April. These interim data...
From innovation to practice: The Ellipsys vascular access system
This is an exciting time for vascular access. Minimally invasive anastomosis devices have been developed and are being utilised in the creation of percutaneous...
